Vivo Capital overview
Stories about Vivo Capital
Vivo Capital closes on $740m for third cycle of evergreen public fund
The fund's private markets-style structure 'allows us to apply a venture capital mindset to publicly traded biotech companies,' says managing partner Gaurav Aggarwal.
KGI Life approves $60m in commitments
The Taiwan-based insurance company has backed two private equity funds.
Serán Bioscience snags investment from Bain Capital Life Sciences
Serán's existing investor Vivo Capital remains a key shareholder in the company.
Vivo Capital taps Massad as business development mnaging director
Massad is a former global head of business development and investor relations at Highbridge Capital Management.
Fubon Life approves $129m in commitments
The Taiwan-based insurance company has backed two private equity funds.
Vivo Capital appoints three to managing partner and promotes two to partner
Vivo Capital has named Dr. Hongbo Lu, Jack Bech Nielsen and Michael Chang to managing partners.
Vivo Capital raises $1.43bn
The Palo Alto-based private equity firm closed its ninth healthcare and life sciences fund above its target.
DMed Biopharma raises $50 mln
DMed Biopharmaceutical Co said it raised roughly $50 million in a Series B funding round led by Vivo Capital. Participating in the round were Legend Capital, Qiming Venture Partners and Lilly Asia Ventures. DMed is a clinical contract research organization that provides industry solutions to pharmaceutical and medical device companies in China and across the globe.
Vivo Capital contact information
Offices
192 Lytton Avenue, Palo Alto, 94301, United StatesContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Dr. Gaurav Aggarwal | Job titleManaging Partner and Chief Investment Officer, Opportunity Fund | LocationPalo Alto, United States | Email  ---------- |
| Key ContactMs. Jane Gong | Job titlePrincipal, Investor Relations | LocationBeijing, China | Email --------- |
| Key ContactMs. Chloe Zhang | Job titlePrincipal, Investor Relations | LocationPalo Alto, United States | Email ----- |
| Ms. Cinthia Sheu | Job titlePartner and Chief Operating Officer | LocationPalo Alto, United States | Email -------- |
Vivo Capital funds managed
Funds in market: 2
| Fund | Fund size | Open date | Strategy |
|---|---|---|---|
Fund size ----------- | Open dateAug 2026 | Strategy ---------- | |
Fund size ------ | Open dateJul 2024 | Strategy ------ | |
Closed funds: 10
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size ----------- | Close dateDec 2023 | Strategy ----- | |
Fund size ----------- | Close dateApr 2022 | Strategy ----------- | |
Fund size -------- | Close dateOct 2019 | Strategy --------- | |
Stories that mention Vivo Capital
Biospring Partners leads growth investment in spray drying CDMO Serán Bioscience
Bend, Oregon-based Serán Bioscience provides development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies.
Vivo Capital taps Neetesh Kumar as managing partner
Kumar will co-lead Vivo’s buyout and private equity investment strategy with a focus on the US market and help establish the firm’s presence in New York.
LBO France to sell Dutscher to Vivo Capital
Dutscher is a European consumables and equipment distribution company.
Venture capital’s 2026 Rising Stars: A-G
A principal focused on AI early-stage investments, a partner concentrating in biotechnology and a principal involved with women’s health research are among those on VCJ's 2026 list of 40 Rising Stars under the age of 40.
A new prescription for US healthcare
Under the second Trump administration, policy change and regulatory scrutiny are steering healthcare investors’ attention towards a different set of opportunities.
Evergreen funds: Good or bad for LPs?
Nicole Musicco, former CIO of CalPERS, warns that evergreen funds may lead to a more transactional dynamic between manager and investor.
Arizona Public Safety hits pause on VC investments
The public pension has committed a combined $95m to venture funds managed by Upfront Ventures, StepStone Group and Mission BioCapital since 2019.
Biotech company enGene to go public in Forbion-sponsored SPAC merger
Upon closing of the deal, the combined company will be named enGene Holdings, whose common shares are expected to be listed on the Nasdaq.